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ABSTRACT 
Breast Cancer remains one of the world’s leading causes of cancer related deaths 
amongst women. Its treatment has evolved from invasive, highly toxic therapies to 
treatments that possess a higher specificity and a lower toxicity. Despite 
improvements in overall survival, many patients do not benefit from these agents 
because of acquired and/or inherent tumour resistance, which could hinder treatment 
efficacy. Novel treatment strategies are, therefore, warranted to address these 
challenges and to significantly improve patient responses. Inhibiting components of 
the HER-2 signalling pathway can significantly sensitise breast cancer cells to low 
doses of ionising radiation. 
The objective of this study was to inhibit key molecular targets of the human 
epidermal growth factor receptor 2 (HER-2) signalling pathway and expose breast 
cancer cell lines to doses of radiation, so as to establish potential therapeutic targets 
that may be amenable to combined modality therapy, and formulate a cocktail of 
inhibitors to evaluate its radiosensitising capability. 
This study found that pre-treatment of two breast cancer cell lines (MDA-MB-231 and 
MCF-7) with a HER-2 inhibitor (TAK-165) had little or no effect on radiosensitivity. 
However, a radiation enhancement was observed when these cells were pre-treated 
either with BEZ235, a dual inhibitor of phosphoinositide 3-kinase (PI3K) and 
mammalian target for rapamycin (mTOR), or a cocktail of TAK-165 and BEZ235. 
These findings suggest that concurrent inhibition of HER-2, PI3K and mTOR during 
radiotherapy might improve treatment response of breast cancer patients.  
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OPSOMMING 
 
Borskanker bly steeds een van die leidende oorsake van sterftes aan kanker in 
vrouens. Behandeling het vanaf ‘n ingrypende, hoogs toksiese terapie verander na ‘n 
regimen wat hoogs spesifiek met ‘n laer toksisiteit is.  Nogtans trek baie pasiënte 
geen voordeel uit hierdie nuwe benadering nie, omdat inherente en/of verworwe 
tumorweerstand daarteen suksesvolle uitkomste verhoed. 
Nuwe behandelingstrategieë is dus nodig om hierdie uitdagings te bekamp en om 
resultate in pasiënte aansienlik te verbeter. 
Inhibisie van komponente van die HER-2-seinoordragkaskade kan borskankerselle 
gevoelig maak vir lae dosisse van geïoniseerde bestraling. 
 
Die doelwit van hierdie studie was om sleutelteikens in die HER-2-
seinoordragkaskade te inhibeer en om borskankerselle daarna aan bestralings 
dosisse bloot te stel. Sodoende word potensiële terapeutiese teikens wat vatbaar is 
vir gekombineerde modaliteitsterapie geïdentifiseer, waarna ‘n kombinasie van 
inhibitore geformuleer en geëvalueer kan word ten opsigte van hulle kapasiteit om 
gevoeligheid vir bestraling te verhoog. 
 
Die studie bevind dat voorbehandeling met ‘n HER-2-inhibitor (TAK-165) van 
borskankersellyne (MDA-MB-231 en MCF-7) min of geen invloed gehad het op 
stralingsensitiwiteit nie. ‘n Stralingsversterking is egter geïdentifiseer toe die selle 
vooraf behandel is met óf BEZ-235, ‘n tweevoudige inhibitor van fosforinositied 3-
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kinase (PI3K) en soogdierteiken vir rapamisien (mTOR), óf ‘n mengsel van TAK-165 
en BEZ-235. 
Hierdie bevindinge suggereer dat gelyktydige inhibisie van die HER-2-
seinoordragkaskade, PI3K en mTOR gedurende stralingsterapie moontlik die 
uitkoms in borskankerpasiënte kan verbeter. 
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1.1. Introduction 
 
Cancer continues to be a major global burden. This is largely attributed to the growth 
and aging of the world’s population, as well as the increased adoption of cancer 
causing behaviours, such as smoking and leading an unhealthy lifestyle (Jemal et 
al., 2011). Breast Cancer is the most frequently diagnosed cancer. Worldwide, 
breast cancer is responsible for 32% of all cancers and 15% of all cancer related 
deaths in females (Salouti et al., 2011). In Africa, approximately 29 and 15 per 
100 000 persons are diagnosed or dies of breast cancer, respectively (Jemal et al., 
2011). In Southern Africa, higher incidence and mortality rates are observed 
corresponding to 38 and 19 per 100 000 persons, respectively (Jemal et al., 2011). 
Consequently, breast cancer has become a significant health concern in Southern 
Africa and the greater African continent. 
Breast cancer is a disease composed of various subtypes, each possessing unique 
molecular characteristics, and therefore having different clinical responses and 
requiring unique treatment modalities (Higgins and Baselga., 2011; Park et al., 2012; 
Perou et al., 2000). Currently, many options are available to treat breast cancer. 
Although these modalities have improved treatment outcomes, many still have 
shortcomings as a consequence of high toxicity and tumour resistance. This clinical 
situation is further exacerbated by the heterogeneity of breast cancer cells. 
Therapeutic approaches targeting specific antigens may also fail as targets are 
expressed at widely varying levels within cell populations. Novel treatment strategies 
are thus warranted to address these clinical challenges. Radiotherapy has been 
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used for decades as the primary therapy for many types of cancers. Exposing cancer 
cells to ionising radiation has proved effective in gaining control of tumour size as it 
invokes lethal damage to cellular DNA and induces apoptosis (programmed cell 
death) (Buchholz, 2009; Duru et al., 2012; Liang et al., 2003; Pearce et al., 2001). 
Today, radiotherapy has become the standard treatment for post-operative breast 
cancer so as to decrease the risk of tumour recurrence (Pinnaro et al., 2010; 
Whelan., 2010). Even though the addition of radiotherapy has improved overall 
disease-free survival of breast cancer patients, many tumours do not respond to 
radiotherapy as these tumours are inherently, or have become, radioresistant (Jung 
et al., 2012, Li et al., 2012; Liang et al., 2003). Radiotherapy is also damaging to 
normal tissue and thus many patients suffer from short-term and long-term side 
effects (Buchholz., 2009). Breast cancer treatment has moved from invasive, non-
specific, highly toxic regimens to modalities that are less invasive and less toxic to 
normal tissue as they are now target specific. 
A deeper understanding of breast cancer cell heterogeneity has led to the 
identification of numerous biological markers which play valuable roles in breast 
cancer cell survival and proliferation. From this, effective targeted therapies which 
inhibit these survival and proliferative signalling markers have been developed; some 
are currently available in the clinic while others remain in the trial phase (Normanno 
et al., 2009). Trastuzumab is the first of these targeted therapeutic agents that has 
successfully been applied in breast cancer treatment. Trastuzumab has shown 
significant clinical activity in targeting the human epidermal growth factor receptor 2 
(HER-2), particularly among the percentage of the breast cancer population that 
overexpresses this receptor. It has been suggested that trastuzumab may be able to 
slow down tumour growth. However, not all breast cancer subtypes express this 
Stellenbosch University  https://scholar.sun.ac.za
4 
 
antigen and thus alternative treatment strategies are required to effectively treat 
these breast cancer subtypes (Hall and Cameron, 2009).  Targeting other survival 
proteins, such as those of the PI3K/Akt/mTOR pathway, could prove to be beneficial 
for low- or non-HER-2 expressing subtypes of breast cancer. The inhibition of these 
proteins has also been implicated in enhancing cancer cell radiosensitisation (Awada 
et al., 2012; Rexer et al., 2014). 
Targeted therapy has improved overall patient survival; however, its treatment 
efficacy has also been hindered by breast cancer cell inherent or acquired resistance 
(Higgins and Baselga., 2011; Hurvitz et al., 2013). It has also been reported that the 
efficacy of targeted therapy is limited when using these agents individually, and that 
using these therapeutic agents in combination would derive better patient responses 
(Normanno et al., 2009). 
It can, therefore, be reasoned that using a cocktail of targeted therapeutic agents to 
inhibit more than one survival signalling targets would be more effective in treating 
breast cancer, than using these agents individually. The objective of the following 
study will be to develop a new therapeutic strategy using radiotherapy in combination 
with agents that target pro-survival signalling components.  
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1.2. Literature Review 
 
1.2.1. Cancer 
Cancer is a somatic disease characterised by the dysregulation of cell proliferation 
and apoptosis. Most cancers are thought to occur as a consequence of a series of 
DNA repair abnormalities which ultimately establish a growth advantage for the 
clones of cancer cells in which these repair processes have occurred (Bamford et al., 
2004). These cells possess the ability to be self-sufficient in growth signals and 
insensitive to anti-growth signalling. Tumour cells generate their own growth signals 
so that they may be independent from growth stimulation from their normal tissue 
microenviroment. The deregulation of growth signals and their respective receptors 
enable cancer cells to be hyperresponsive to growth stimuli that would normally not 
trigger its development. It also allows these cells to remain independent from 
external growth factors. These characteristics assist in cancers ability to evade 
apoptosis and replicate continuously (Hanahan and Weinberg., 2000 and 2011).      
Many cancers also sustain themselves through the initiation and development of new 
blood vessels (angiogenesis), which provide nutrients and oxygen. These cells may 
alter their energy metabolism to a state which could favour the development of new 
cancer cells. Cancer cells are able to spread (metastasise) from their original 
location to other parts of the body, or infiltrate the surrounding tissue. (Hanahan and 
Weinberg., 2000 and 2011). These unique characteristics could, in part, contribute to 
the current challenges faced in the clinic.  
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Cancer progression is generally described in stages using roman numerals; stage 0 
is when a carcinoma is found in situ. Cancer is at stage I when it is localized to one 
part of the body and stage II cancer is diagnosed when these cells start to invade 
surrounding tissue on one side of the body. Stage III cancer has also been 
categorised as, when cancer has advanced locally and a patient is diagnosed with 
stage IV cancer when this disease had metastasised (Maughan et al., 2010).  
Kruger and colleagues have reported that membrane vesicles released into the 
extracellular environment by malignant cells could play a role in tumour progression. 
These vesicles known as exosome-like vesicles play a major role in cell-to-cell 
communication. These vesicles may contain oncogenic molecules that may convey 
oncogenic signals to non-malignant cells. Kruger et al, has also reported that these 
vesicles contain molecules which could give insight into a particular cancer that the 
body might be suffering from, in the case of Kruger et al they looked at breast 
cancer. They have found that exosomes of MDA-MB-231 and MCF-7 (both breast 
cancer cell lines) express calmodulin, which regulates the Akt pathway and is 
associated with poor prognosis in breast cancer patients (Kruger et al., 2014). These 
exosomes could provide vital information about a specific type of cancer and may 
assist in the detection of cancer as well.    
Approximately 200 different types of cancers exist, their characteristics depending on 
the tissue of origin (Madani et al., 2011). Breast cancer will be investigated in this 
study.  
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1.2.2. Breast Cancer 
Originating from mammary gland epithelium, breast cancer is a heterogeneous 
disease composed of multiple subtypes with unique molecular features. This results 
in distinctive clinical responses (Park et al., 2012; Perou et al., 2000). Gene 
expression profiling studies have established four major molecular classifications in 
which these subtypes are categorised. These groups are: Luminal A; Luminal B; 
HER-2-enriched; and basal cell-like (Perou et al., 2000; Sorlie et al., 2001; 2003). 
Luminal A or B breast cancer are breast tumours that express progesterone 
receptors (PR), oestrogen receptors (ER), and low levels to no expression of the 
human epidermal growth factor receptor 2 (HER-2) (Adelaide et al., 2007; Phipps et 
al., 2008). HER-2 enriched breast cancer overexpresses the HER-2 membrane 
receptor (Adelaide et al., 2007). The basal cell-like subtype of breast cancer does 
not express PR, ER or HER-2 and is thus known as a triple negative subtype 
(Adelaide et al., 2007; Phipps et al., 2008). Luminal A and B subtypes are 
considered to have a better prognosis, as they express essential therapeutic targets 
required for current targeted therapies. The basal cell-like subtype constitutes about 
17% of the breast cancer population and is associated with a poor prognosis as this 
subtype has a ‘triple negative’ phenotype, meaning it does not express ER, PR or 
HER-2, which are essential therapeutic targets (Foulkes, Smith and Reis-Filho., 
2010). Therefore, this subtype is considered to be highly aggressive and difficult to 
treat. This may not only be attributed to the lack of therapeutic targets (Adelaide et 
al., 2007; Park et al., 2012; Phipps et al., 2008).   
Approximately 20-30% of the breast cancer patient population overexpress HER-2, 
which is regarded as the HER-2 enriched subtype, and is associated with a poor 
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clinical prognosis as the amplification of HER-2 has been implicated in enhanced 
tumour aggressiveness, higher risk of relapse and reduced survival (Adelaide et al., 
2007; Molina et al., 2001). This can potentially be attributed to HER-2 being the 
major component of a signalling pathway which conveys cell survival signals through 
transducer proteins and DNA transcription regulators (Bombonati et al., 2012; 
Gutierrez et al., 2011). However, a significant percentage of breast cancer patients 
do not overexpress HER-2, thus, cancer cells would not completely rely on HER-2 to 
ignite this survival pathway and a subset of patients would not benefit from anti-HER-
2 therapy.     
 
1.2.3. HER-2 Signalling Pathway 
The human epidermal growth factor receptor-2 (HER-2/neu, erbB2) is a member of 
the transmembrane tyrosine kinase receptor family, also known as the epidermal 
growth factor receptor family, which consists of HER-1 (erbB1); HER-2; HER-3 
(erbB3); HER-4 (erbB4) (Bombonati et al., 2012; Gutierrez et al., 2011). The HER-2 
signalling pathway is a complex network consisting of three stages (Figure 1). These 
stages encompass the tyrosine kinase membrane receptor family and their specific 
ligands which activate the pathway, transducers which transmit this activating signal 
down the pathway, and effector proteins which regulate the expression of genes 
controlling tumour cell survival (Bombonati et al., 2012; Gutierrez et al., 2011).  
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Figure 1: Human epidermal growth factor receptor family signal 
transduction pathways. Homodimerisation and heterodimerisation of 
HER-2 leads to tyrosine kinase activation and downstream signalling via 
the PI3K/Akt/mammalian target of rapamycin pathway, and the 
Ras/Raf/mitogen-activated protein kinase pathway to stimulate 
processes involved in cell survival and proliferation (Hurvitz et al., 2013). 
 
HER-2 has no known ligand and thus forms hetero- and homodimers to activate the 
survival signalling pathway. The phosphorylation of these dimers results in the 
activation of a sequence of downstream transducer proteins, including 
phosphoinositide 3-kinase (PI3K), serine-threonine protein kinase (Akt), and 
mammalian target for rapamycin (mTOR).  
Stellenbosch University  https://scholar.sun.ac.za
10 
 
Activation of mTOR results in the phosphorylation of protein synthesis regulators, 
and can lead to the differential expression of genes involved in cell survival, cell 
growth, and many other vital cellular functions. Dimerisation of the tyrosine kinase 
receptors family is not only a method of activating the survival pathway, but also a 
way of diversifying this activating signal to ensure that there is more than one form of 
dimer that could activate the HER-2 signalling pathway (Hurvitz et al., 2012). 
Alternate activators of the HER-2 signalling pathway have also been discovered. 
Nahta and colleagues have reported that HER-2 is also phosphorylated by 
dimerising with insulin-like growth factor-1 receptor, demonstrating that activation of 
the HER-2 survival pathway may not completely depend on the epidermal growth 
factor receptor family (Nahta et al., 2005). 
 
1.2.4. Breast Cancer Therapy 
Breast cancer subtypes, as listed in Table 1, have different epidemiological risk 
factors, unique biological histories and different responses to therapy. These 
characteristics suggest that each breast cancer subtype will not respond to the same 
treatment in the same manner and would thus require individualized treatment 
regimens. Table 1 depicts the recommended treatment regimens for specific 
subtypes of breast cancer (Goldhirsch et al., 2011). 
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Table 1: Breast cancer subtypes and their recommended therapy 
Breast Cancer Subtype Recommended Therapy: 
Luminal A Endocrine therapy 
Luminal B Endocrine Therapy, cytotoxic therapy 
and anti-HER-2 therapy   
HER-2 enriched Cytotoxic therapy and anti-HER-2  
Basal-like Cytotoxic therapy 
(Goldhirsch et al., 2011)  
 
The therapeutic options for breast cancer are generally determined by the tumour-
node-metastasis staging. Lymphovascular spread, histologic grade, hormone 
receptor status, HER-2 overexpression, the presence of other disorder, as well as 
the menopausal state and age of the patients are also important factors to consider 
(Maughan et al, 2010). Table 2 depicts the typical therapeutic options for each stage 
of breast cancer.  
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Table 2: Treatment options for Breast cancer by Stage  
Breast cancer Stage: Typical Therapy: 
Stage 0: in situ 
 
 
No treatment or consider prophylaxis 
with tamoxifen 
or 
Breast-conserving  surgery (consider 
mastectomy if extensive or multifocal and 
radiotherapy 
 
Stage I and II: Early stage invasive 
 
Breast-conserving surgery and 
radiotherapy 
 
Stage III: Locally advanced 
 
Chemotherapy followed by breast 
conserving therapy or mastectomy and 
radiotherapy 
 
Stage IV: Metastatic 
Address patient’s treatment goals; 
radiation and bisphosphate for pain 
 
(Maughan et al, 2010) 
 
At stage 0 breast cancer, there are two types of carcinomas that require different 
treatment approaches. Lobular carcinoma in situ is a minor finding of an abnormal 
tissue growth in the lobule of the breast, and does not progress to invasive breast 
cancer. Ductal carcinoma in situ can progress to invasive breast cancer. The 
standard therapy for a ductal carcinoma in situ is breast conserving surgery followed 
with radiotherapy; however a mastectomy may be recommended for multifoci 
disease (Maughan et al., 2010). 
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For patients with stages I and II cancer, surgery has become the standard 
therapeutic regimen. Breast-conserving surgery has now become the preferred 
treatment over the traditional modified radical mastectomy. The outcome of this 
surgery is more aesthetically pleasing to the patient as only the tumour is removed 
leaving behind the healthy mammary tissue, unlike the radical mastectomy where 
the whole breast is removed. Radiotherapy is given after the breast conserving-
surgery; this decreases the chances of local recurrence and improves patient 
survival rates. Breast conserving surgery has the highest success rate in women 
with early-stage breast cancer (Maughan et al., 2010). 
 When breast cancer has advanced into the surrounding tissue and includes tumours 
larger than 5 cm, extensive regional lymph node involvement, as well as the chest 
wall and skin, and if these tumours are considered inoperable, and the disease is 
classified as stage III breast cancer. Chemotherapy with surgery and radiotherapy is 
recommended for this stage of breast cancer. A 5-year survival rate of 55% may be 
achieved in patients with stage III breast cancer (Maughan et al., 2010). 
Metastatic breast cancer is the final stage. Patients who relapse after being treated 
for stage I, II, or III breast cancer may present with metastatic disease. A 5-year 
survival rate of only 23.3% may be attained in of these patients. Treatment with 
radiation or bisphosphonates, endocrine therapy or chemotherapy may assist in 
managing pain. Although chemotherapy and endocrine therapy can be tolerated, 
they inevitably have side effects. Trastuzumab alone or in combination with 
chemotherapy may be used as treatment for metastatic cancer overexpressing 
ERBB2 (HER-2) (Maughan et al., 2010). 
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Breast cancer therapy has progressed from highly invasive, non-specific, extremely 
toxic interventions to treatment modalities that are less invasive, highly specific and 
less toxic. Although there has been a significant improvement in breast cancer 
treatment, as well as the number of treatment options available, patient benefit has 
been suboptimal (Verbrugge et al., 2014). Therefore, new treatment strategies are 
warranted that would maximise beneficial patient response. For the purposes of this 
study radiotherapy and targeted therapies will be the investigated. 
 
1.2.4.1. Radiotherapy 
Ionising radiation has been used for years as the primary treatment for many types 
of cancers (Yacoub et al., 2006). Radiotherapy can cause cell death through the 
generation of free radicals which induce high levels of cellular DNA damage 
(Buchholz 2009; Duru et al., 2012; Pearce et al., 2001). 
Radiotherapy is a significant primary treatment for breast cancer as it plays an 
essential role in the local control of the disease (Liang et al., 2003). Randomised 
clinical trials have reported that the addition of radiotherapy as an adjuvant to other 
treatment regimens for breast cancer improves overall disease-free patient survival 
(Li et al., 2012; Liang et al., 2003). This therapy has become the standard treatment 
after breast conserving surgery for patients with early stage cancer as it reduces the 
risk of local recurrence and can assist in preventing the need for mastectomy 
(Pinnaro et al., 2010; Whelan., 2010). Despite advances in early diagnosis and 
treatment efficacy, death due to breast cancer remains high, and has been attributed 
to treatment evasion by metastatic tumours and the recurrence of primary tumours 
(Duru et al., 2012).  
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Radioresistant breast cancer cells are able to survive during radiation exposure, thus 
increasing the risk of tumour recurrence. Cellular exposure to ionising radiation has 
been known to activate HER-2 and the downstream effectors of the HER-2 survival 
pathway (Escriva et al., 2008; Contessa et al., 2002). In some cases, HER-2 
overexpression in cancer cells may indicate resistance to radiation by a variety of 
biochemical pathways through the activation of signalling molecules. Mammalian 
cells express various proteins in response to ionising radiation, suggesting that cells 
exposed to radiation can be manipulated by a particular survival signalling network 
(Amundson et al., 2004; Bisht et al., 2003).  
A tumour may consist of several distinct subpopulations of cells that may respond 
differently to radiation therapy (Forrester et al., 1999). Radioresistant tumours are 
thus a significant clinical obstacle as they limit the effectiveness of radiotherapy 
(Duru et al., 2012; Li et al., 2012).   
 
1.2.4.2. Targeted Therapy 
The understanding that breast cancer is a disease composed of various subtypes, 
each possessing unique molecular characteristics that can lead to a variety of clinical 
responses, has led to the identification of various biological markers which play an 
essential role in signalling pathways that regulate cancer cell survival and 
proliferation. These markers paved the way for the development of target-based 
therapies that are highly specific, less invasive and less toxic than conventional 
treatment (Normanno et al., 2009). Tyrosine kinase inhibitors (TKIs) directed at a 
number of targets (HER-1, HER-2, HER-3 and IGF receptors), intracellular signalling 
pathway inhibitors (PI3K, Akt, mTOR), angiogenesis inhibitors, and agents that 
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interfere with DNA repair are among the examples of targeted therapies. Some of 
these treatments have been shown to be effective in managing breast cancer and 
have become the standard in breast cancer patient care (Higgins and Baselga., 
2011).  
Trastuzumab and lapatinib are two examples of clinically available targeted therapies 
that have become standard treatments for HER-2 positive breast cancer. 
Trastuzumab is a monoclonal antibody which targets the extracellular domain of the 
HER-2 receptor, and lapatinib is a tyrosine kinase inhibitor that targets the 
intracellular domain of HER-2 and epidermal growth factor receptor. Despite the 
overall improvement in survival seen with the addition of targeted therapy to other 
treatment regimens, many breast cancer patients do not benefit as a result of 
treatment resistance (Hurvitz et al., 2013). Acquired tumour resistance has been 
attributed to the loss of target expression as a result of continuous exposure to 
therapy and the activation of additional pathways that promote cell survival (Higgins 
and Baselga., 2011). The heterogeneity in the distribution of target expression can 
contribute to targeted treatment resistance. A particular cell population may exhibit a 
wide variation in the distribution of the antigen of interest, with some cells showing 
little or no target expression. This can lead to the inability to effectively target all cells 
of a specific subpopulation with toxic levels of a therapeutic agent. The phenomenon 
has been demonstrated for radiopharmaceuticals, chemotherapeutic drugs, and 
radioimmunotherapeutics (Akudugu and Howell, 2012a, b; Akudugu et al., 2011; 
Kvinnsland et al., 2001). Change in target morphology can also limit treatment 
efficacy. A change in antigen shape would make it difficult for the antigen specific 
treatment agent to bind to the relevant target and exert its toxic action. This is 
observed when breast cancer cells express the truncated HER-2 (p95HER-2). The 
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p95HER-2 lacks the epitope for trastuzumab, which is found in the full length version 
of this receptor. This makes these cells resistant to trastuzumab therapy (Zagozdzon 
et al., 2011). The development of resistance to targeted therapies is an ongoing 
challenge that may be addressed by novel treatment strategies (Higgins and 
Baselga, 2011).  Targeted therapy is not only limited to anti-HER-2 targeted therapy; 
there are other options available which depends on the subtype of breast cancer. 
Hormone therapy stops growth hormone sensitive tumours by preventing the body 
from producing these hormones or by interfering with the action of these hormones, 
an example is aromatase inhibitors which blocks oestrogen production by disrupting 
the conversion of androgens to oestrogens (Maughan et al., 2010). Other targeted 
therapies are signal transduction inhibitors, gene expression modulators, apoptosis 
inducers, angiogenesis inhibitors and immunotherapies. This study will focus on 
another form of targeted therapy, tyrosine kinase inhibitors.      
There is an immense interest in tyrosine kinase inhibitors as many of these have 
been shown to be effective anti-cancer agents (Moasser et al., 2001). Tyrosine 
kinase inhibitors are molecules that compete with adenosine triphosphate (ATP) at 
the binding site of the respective tyrosine kinase receptor. This results in the 
blockage of receptor phosphorylation and subsequent signalling to survival and 
proliferating pathways (Roy et al., 2009). Tyrosine kinase inhibitors have displayed 
an ability to affect trastuzumab resistant cancer cells and have several advantages 
over monoclonal therapy (Lin and Winer., 2004).  These inhibitors are active against 
the truncated forms of HER-2 receptors in vitro (Lin and Winer., 2004). They are 
biologically available and well tolerated, when compared with trastuzumab. Also, 
they may be manipulated to target more than one receptor family simultaneously 
(Spector et al., 2007; Lin and Winer., 2004). 
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The overexpression of HER-2 is not the only contributing factor to trastuzumab 
resistance in breast cancer. The activation of the PI3K/Akt/mTOR pathway has been 
implicated in trastuzumab resistance (Chandarlapaty et al., 2012). These proteins, 
PI3K; Akt; and mTOR, have also been shown to be activated by cellular exposure to 
ionising radiation as they convey signals that lead to cell survival. This justifies the 
investigation of inhibitors which target HER-2 and the downstream PI3K/Akt/mTOR 
pathway, as the inhibition of these proteins would lead to the cessation of survival 
signals and result in improved treatment response. 
 
1.2.4.2.1. TAK-165 
TAK-165 (Millenium Pharmaceuticals, Inc, Cambridge, MA) is a tyrosine kinase 
inhibitor which targets HER-2 and has shown activity in breast cancer 
overexpressing HER-2 (Spector et al., 2007).  
 
1.2.4.2.2. NVP-BEZ235 
The PI3K pathway is a component of the HER-2 signalling pathway that a cell 
requires for the propagation of survival and proliferative signals. The activation of this 
pathway is commonly found in human cancers. The inhibition of this pathway may 
result in a variety of genetic and epigenetic abnormalities, which can produce PTEN 
mutations and the amplification of HER-2 which promotes treatment resistance. The 
PTEN gene provides instructions for making a protein that is found in almost all 
tissues in the body. The protein acts as a tumour suppressor, regulating the cycle of 
cell division by keeping cells from growing and dividing too rapidly or in an 
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uncontrolled way. Mutations in the PTEN gene result in an altered protein that has 
lost its tumour suppressor function. The loss of this protein's function likely permits 
certain cells to divide uncontrollably, contributing to the growth of cancerous tumours 
Barlund et al., 2000; Jefferies et al., 1997; Klos et al., 2006). Targeted therapy 
against specific components of this pathway appears to be effective as single 
agents, or in combination, in various human cancers (Brachmann et al., 2009).  
NVP-BEZ235 (BEZ235; Novartis Pharma) is a low molecular weight molecule 
imidazoquinoline that inhibits the class 1 PI3K and mTOR catalytic activity by 
competing at the ATP-binding site (Maira et al., 2008). In a study by Brachmann and 
colleagues, it was determined that BEZ235 exhibited both antiproliferative and 
cytotoxic activities (Brachmann et al., 2009). While BEZ235 caused cell death in cell 
lines MDA-MB-453; MCF-7; MDA-MB-361; SKBr3 and HCC141, it inhibited 
proliferation in cell lines MDA-MB-231 and MDA-MB-468. The study further showed 
that BEZ235 efficiently shuts down the PI3K pathway in HER-2 amplified cells, and 
induces cell death via active apoptotic processes that preferentially require the 
activation of the initiator, caspase-2 (Brachmann et al., 2009). Ultimately, it was 
concluded that BEZ235 would be most effective for breast cancer with HER-2 and/or 
PI3K mutations. This provides a strong rationale for phase II studies using BEZ235 
alone or in combination with anti-HER-2 therapy.  
 
1.2.5. Combination Therapy  
Combination therapy aims to overcome the limitations of monotherapy by modulating 
various therapeutic targets to synergistically enhance therapy effectiveness. In 
combination therapy, one molecule may improve the action of another by increasing 
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its penetration or preventing its destruction (Reece et al., 2007). A two-fold rationale 
has been suggested for the use of concomitant therapy. Firstly, when multiple drugs 
with different targets are applied, cancer cell adaption such as mutations can be 
delayed. Secondly, multiple drugs targeting the same cellular pathway could function 
synergistically for higher therapeutic efficacy and higher target selectivity (Lee and 
Nan, 2012).    
Preclinical data show that using multiple antibodies directed against the HER family 
in combination with various tyrosine kinase inhibitors may lead to therapeutic 
strategies that selectively diminish oncogenic-related signalling and result in 
remarkable anti-tumour activity. This treatment strategy could possibly overcome 
treatment resistance (Nielsen et al., 2008). 
It has been suggested that targeting the HER-2 pathway may increase the anti-
tumour activity of ionising radiation (No et al., 2009). In this regard, it was shown that 
LY294002, a PI3K inhibitor, can inactivate the PI3K/Akt/mTOR pathway and 
significantly attenuate the expression of p-70S6K and phosphorylation of Akt leading 
to radiosensitisation of SKBR3 cells (No et al., 2009). The 70-kDa ribosomal protein 
S6 kinase (p-70S6K) is a serine/threonine kinase that regulates protein translation by 
phosphorylating ribosomal protein S6. p-70S6k is downstream of the 
phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (mTOR) pathway, 
which is activated by HER-2, insulin-like growth factor receptor, and oestrogen 
receptor in breast cancer. Patients with tumours having increased p-70S6K 
phosphorylation have worse disease-free survival and increased metastasis, which 
shows the importance of p-70S6K in breast malignancy. This suggests that selective 
targeting of downstream signalling in combination with radiation as a potential 
therapeutic approach may defeat resistance to HER-2 therapy.  
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Serra and colleagues reported that when the PI3K pathway is inhibited by BEZ235, 
the activity of compensatory pathways such as those involving the HER gene, 
increases (Serra et al., 2011). This suggests that PI3K and HER-2 activities are 
connected through a feedback loop. When the phosphorylation PI3K pathway is 
inhibited, the cell increases the phosphorylation of HER-2 so as to send the signal 
downstream to increase phosphorylation of PI3K and increase signalling to Akt and 
mTOR. It is thus conceivable that when HER-2 phosphorylation is inhibited, the cell 
increases the phosphorylation of PI3K through alternate signalling proteins. Thus 
targeting both these proteins using a combined therapeutic modality would be 
effective in inhibiting tumour cell growth. BEZ235, which targets PI3K and mTOR, in 
combination with lapatinib and trastuzumab, which targets HER-2, emerged more 
effective in reducing cell proliferation than when these agents were used individually 
(Serra et al., 2011). Deregulation of the PI3K/Akt pathway sensitises cells to 
radiation (Riesterer et al., 2004). The current study will seek to manipulate the 
radiosensitivity of breast cancer cell lines MDA-MB-231 and MCF-7 by exposing 
them to a cocktail of TAK-165 and BEZ235. This will assist in deciphering if exposing 
breast cancer cells to a cocktail of survival pathway inhibitors can enhance cellular 
radiosensitivity, and provide insights into formulating novel therapeutic approaches. 
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1.3.  Problem Statement 
 
Contemporary breast cancer treatment modalities have improved patient outcomes. 
However, many do not benefit from these approaches as various clinical challenges 
still exist. Inherent and acquired resistance to treatment are just two of these 
challenges (Higgins and Baselga., 2011; Hurvitz et al., 2013). The inability to 
effectively target malignant cells with toxic levels of a single agent has been 
attributed to the heterogeneous expression of target antigens. This phenomenon has 
been demonstrated for radiopharmaceuticals, chemotherapeutic drugs and 
radioimmunotherapeutics (Akudugu and Howell, 2012a, b; Akudugu et al., 2011; 
Kvinnsland et al., 2001).  Treatment of most cancers with a single agent has, 
therefore, had limited success and novel treatment strategies are crucial in 
addressing these therapeutic challenges.       
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1.4. Hypothesis 
 
Inhibiting components of the HER-2 signalling pathway can significantly sensitise 
breast cancer cells to low doses of ionising radiation.  
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1.5. Aims and Objectives 
 
This study aimed to identify potential therapeutic targets in breast cancer cell lines 
through the use of known inhibitors of the HER-2 survival pathway and the 
downstream components of this pathway. Additionally, to evaluate the effect these 
inhibitors would have individually and combined as radiosensitizers.  
To achieve these specific aims this study’s objectives are as follows: 
1. To determine the relative survival of MDA-MB-231 and MCF-7 cell lines after 
exposure to ionising radiation doses ranging from 0 - 10 Gy to determine the 
normal radiosensitivity of these cell lines.  
2. Treat the aforementioned breast cancer cells with a dose of TAK-165 or 
BEZ235, and expose them to ionising radiation. 
3. Determine cell survival after treating these cells with an inhibitor and ionising 
radiation exposure, also to determine target protein expression. 
4. To make-up inhibitor cocktails. 
5. Treat cells with inhibitor cocktails and expose them to ionising radiation. 
6. To determine cell survival after their aforementioned therapeutic approach 
and determine radiation enhancement factors. 
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CHAPTER 2 
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2. Materials and Methods 
 
2.1. Cell lines 
2.1.1. MCF-7 
MCF-7 is a human mammary adenocarcinoma-derived cell line established from a 
metastatic lesion. MCF-7 is classified as a luminal A breast cancer subtype (Subik, 
et al. 2010). It has an epithelial-like morphology, is adherent and grows as a 
monolayer in Roswell Park Memorial Institute medium (RPMI-1640) (Sigma-Aldrich, 
USA), supplemented with 10% heat-inactivated foetal bovine serum (FBS) (HyClone, 
UK), penicillin (100 U/ml) and streptomycin (100 µg/ml) (Lonza, Belgium). A frozen 
vial of cells was obtained from Professor S. Prince (University of Cape Town, South 
Africa).  
 
2.1.2. MDA-MB-231 
MDA-MB-231 is a human mammary adenocarcinoma-derived cell line established 
from a metastatic lesion. MDA-MB-231 is classified as a basal-like breast cancer 
subtype (Subik, et al. 2010). It has an epithelial-like morphology, is adherent and 
grows as a monolayer in RPMI-1640 medium (Sigma-Aldrich, USA), supplemented 
with 10% heat-inactivated foetal bovine serum (FBS) (HyClone, UK), penicillin (100 
U/ml) and streptomycin (100 µg/ml) (Lonza, Belgium). The cells were obtained from 
Professor S. Prince (University of Cape Town, South Africa). 
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2.2. Cell Culture Maintenance    
All cell cultures were kept at 37ºC in a humidified atmosphere of 95% air and 5% 
CO2 in SHEL LAB incubators (Sheldon Manufacturing Inc., USA), and procedures were 
carried out in vertical laminar flow cabinets using aseptic techniques. Cells were 
routinely grown in 75 cm2 flasks, and were passaged when culture confluency was 
between 80 to 90%. For cryopreservation, cells were trypsinised, pelleted by 
centrifugation (4000 RPM for 5 minutes), resuspended in a mixture of 0.9 ml foetal 
bovine serum and 0.1 ml of dimethyl sulfoxide (DMSO), stored at -80°C overnight, 
and then transferred into liquid nitrogen for use at a later stage. The MCF-7 and 
MDA-MB-231 (MDA) cell lines were used in all experiments at passage numbers 
ranging from 39-49 and 18-28, respectively.                
 
2.3. Irradiation Procedure 
Cell lines grown in 25 cm2 tissue culture flasks were irradiated using a 60Co -
irradiation source at the Tygerberg Academic Hospital. Dosimetry was by 
thermoluminescent dosimetry (TLD-chips). The beam configuration was vertical with 
a source-to-sample distance (SSD) of 66.5 cm measured to the base of the 
experimental flasks. The field size was 30 x 30 cm2. Build-up consisted of 10 ml of 
medium in the 25 cm2 culture flasks, and a 0.5 cm perspex sheet positioned on top 
of the culture flasks. The backscatter radiation was absorbed by a 5 cm thick 
perspex sheet and an 8.5 cm thick foamalite slab.  
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For all assays, cell cultures were irradiated at room temperature (22°C) over a dose 
range of 0 - 10 Gy at an average dose rate of 0.827 Gy/min (range: 0.782 - 0.873 
Gy/min).  
 
2.4. Clonogenic Cell Survival Assay 
To determine the relative radiosensitivities of the breast cancer cell lines used in this 
study, clonogenic cell survival assays were performed. Near-confluent stock cultures 
were washed with sterile phosphate buffered saline (PBS), trypsinised, and the cells 
counted using a haemocytometer. The cells were then seeded in triplicate per 
experiment in 25 cm2 culture flasks at numbers ranging from 500 - 10 000 per flask, 
depending on radiation absorbed dose, and left to settle for 3 - 5 hours before being 
exposed to ionising radiation. Cells were irradiated to graded doses ranging from 0 - 
10 Gy. After an appropriate incubation period (usually 7-10 days),  the colonies were 
fixed by decanting the medium in the flask, and replacing that with 10 ml of fixative, 
consisting of 100 ml glacial acetic acid, 100 ml methanol and 800 ml distilled water, 
for 10 minutes.  The fixative was then decanted and replaced with 10 ml of Amido 
Black stain, consisting of 10 ml of 0.01% amido black in 1 litre of fixative. The 
colonies were left to stain for 10 minutes. The stain was then decanted, and the 
flasks left to dry. The colonies were counted using a dissection microscope. The 
means (± SD) of the surviving fractions for three experiments were plotted against 
the irradiation dose, cell survival curves were obtained by fitting the data to the 
linear-quadratic survival equation: 
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𝑆𝑢𝑟𝑣𝑖𝑣𝑎𝑙 (𝑆) = 𝑒−(𝐷+𝛽𝐷
2)    (1) 
 
where S is the surviving fraction, α and β are the linear and quadratic cell inactivation 
constants, respectively, and D is the dose in Gy (Fertil et al., 1984).  
 
2.5. Target Inhibitors  
BEZ235 is a dual inhibitor of PI3K and mTOR; and has a molecular weight of 469.55 
and chemical formula C30H23N5O (Santa Cruz Biotechnology, Texas, USA). The 
inhibitor was dissolved in dimethyl sulfoxide (DMSO) to give a stock solution of 106 
mM, which was stored at -20°C until used. BEZ235 has an inhibitory concentration 
(IC50) of ~7 nM for p110 activity in breast cancer cell lines: CCL-247, HTB-38 and 
HTB-20 (Maira et al., 2008).   
 
TAK-165 is an inhibitor of the human epidermal growth factor receptor 2 (HER-2) 
tyrosine kinase; and has a molecular weight of 468.47, and chemical formula 
C25H23F3N4O2 (Tocris, UK). It was also dissolved in DMSO to a stock of 21 mM and 
stored at 4ºC until needed.  TAK-165 is known to have an IC50 of 6 nM for HER-2 
activity in the BT474 breast cancer cell line (Nagasawa et al., 2006). 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
30 
 
2.6. Effect of inhibitors on radiation response    
Radiosensitisation induced by inhibitors, BEZ235 and TAK-165, added 30 minutes 
prior to irradiation was assessed by clonogenic assay in the MCF-7 and MDA-MB-
231 cell lines. Cell cultures were exposed to inhibitors for the duration of the colony 
formation experiments. For HER-2 inhibition, breast cancer cells were exposed to 
TAK-165 at a concentration of 30 nM (~4  IC50 for HER-2 activity in the BT474 
breast cancer cell line (Nagasawa et al., 2006)). To inhibit PI3K and mTOR, BEZ235 
was administered at a concentration of 17.5 nM (~2.5  IC50 for p110 activity in 
breast cancer cell lines: CCL-247, HTB-38 and HTB-20 (Maira et al., 2008)). The use 
of the relatively high concentrations of TAK-165 was to ensure adequate inhibition of 
the targets. A cocktail of TAK-165 and BEZ235 was also formulated to inhibit all 
three critical targets of the HER-2 signalling pathway. These agents were used at the 
same concentration in combination as when used individually. The final 
concentration of DMSO in cell cultures was 0.2%. Control cultures were not treated 
with DMSO vehicle, as vehicle concentrations up to 5% has been shown to be non-
toxic in the MCF-7 cell line (Gao and Meléndez, 2010). Also, no cytotoxicity was 
demonstrated at a 10% DMSO concentration in Caco2/TC7 colon cell cultures (Da 
Violante et al., 2002).  
Cells were seeded in 25 cm2 tissue culture flasks in numbers ranging from 1000 - 
6000 cells per flask, depending on radiation dose. After cell attachment and inhibitor 
treatment, the flasks were irradiated to 0, 2 and 6 Gy with 60Co -irradiation. After an 
incubation period of 7 - 10 days, colonies were fixed, stained, and counted. The 
corresponding surviving fractions were calculated. Unirradiated cell cultures, with 
and without inhibitors, served as controls.  
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Radiosensitisation by inhibitors was expressed as a radiation enhancement factor 
(REF), given by the ratio of surviving fractions, with and without inhibitor: 
 
REF2Gy =
SF (2 Gy)
SF (2 Gy+inhibitor)
  (2) 
or 
REF6Gy =
SF (6 Gy)
SF (6 Gy+inhibitor)
  (3) 
The criteria for inhibition, no effect, and enhancement of radiosensitivity by inhibitors 
were REF < 1.0, REF  1.0 and REF > 1.0, respectively (Akudugu and Slabbert., 
2008). 
 
2.7. Protein Extraction   
Total protein extraction from all cell lines was performed on ice (4°C). Cells were 
harvested at 0 and 6 hours after radiation with 0 and 2 Gy. The medium was 
decanted and the cells rinsed with cold PBS. Cells were then mechanically 
harvested as a cell suspension in fresh growth medium by gentle scraping with a cell 
scraper. The cell suspensions were then pelleted by centrifugation (4000 RPM for 5 
minutes), washed and resuspended in cold PBS, followed by a second 
centrifugation. The pellets were then resuspended in 250 µl TBS/1%Triton X-100 
extraction buffer supplemented with 10 µl of protease inhibitor cocktail and 10 µl 
phosphatase inhibitor cocktail (Sigma-Aldrich, USA), and placed on a tube roller 
mixer overnight at 4°C. Lysates were clarified by centrifugation (15000 RPM for 15 
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minutes) to remove cellular debris, and the supernatants were collected and stored 
at -80°C.  
 
2.8. Protein Concentration Determination 
Protein determination was performed on ice (4°C) by means of the bicinchoninic acid 
colorimetric assay kit, manufactured by Pierce (Rockford, IL, USA).  Samples were 
diluted in TBS/1%Triton X-100 buffer (1:1 and 1:5), and 10µl of the diluted protein 
placed in a 96-well multiwell plate.  Two hundred microliters of working reagent 
(Reagent A, containing sodium carbonate, sodium bicarbonate, bicinchoninic acid 
and sodium tartrate in 0.1 M sodium hydroxide, and Reagent B containing 4% cupric 
sulphate were mixed in a 51:1 ratio, to produce a clear light green solution) was 
added to each well, and the plate incubated at 37°C for 30 minutes.  A purple colour 
developed. The reaction was stopped by placing the multiwell plate at 4°C for 10 
minutes before the absorbance values were measured with a Labtech L-4000 
microplate reader (Sussex, UK) at a wavelength of 570 nM. 
Serial dilutions were made from a 2 mg/ml bovine serum albumin (BSA) stock vial. A 
standard curve was produced by plotting the average blank-corrected 570 nm 
measurement for each BSA standard against its concentration in μg/ml. The working 
range of the assay was 125 - 2000 µg/ml. 
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2.9. SDS-Polyacrylamide Gel electrophoresis 
2.9.1. Preparation of Acrylamide Gels 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to determine changes in the expression of PI3K, mTOR and HER-2 proteins. This 
method separates proteins by the relative distance they travel across a 
polyacrylamide gel matrix, based on their molecular weights. 
A 10% separating gel, with a 5% stacking gel, was used for optimum resolution of 
the PI3K, mTOR and HER-2 proteins. Briefly, the separating gel was prepared by 
mixing volumes of the following components: 5.9 ml of distilled water, 5 ml of 30% 
acrylamide/Bis solution 29:1 (3.3%), 3.8 ml of 1.5 M Tris (pH 8.8) and 150 µl of 10% 
SDS. One hundred and fifty microlitres of freshly prepared 10% ammonium 
persulfate and 40 µl of tetramethylethylenediamine (TEMED) were added to initiate 
the polymerisation reaction. The stacking gel was prepared as follows: 2.7 ml of 
distilled water, 670 µl of 30% acrylamide/Bis solution 29:1 (3.3%), 500 µl of 1.5 M 
Tris (pH 6.8) and 40 µl of 10% SDS. 40 µl of freshly prepared 10% ammonium 
persulfate and 20 µl of TEMED were added to initiate the polymerisation reaction. 
Using a Pasteur pipette, isopropanol was gently layered on the top of the resolving 
gel to allow polymerisation to proceed in the absence of oxygen. 
Samples were boiled at 95°C for 5 minutes in Laemmli sample buffer (Bio-Rad, USA) 
before loading onto the gel. Equivalent amounts of protein (60 µg) were loaded per 
lane. Twenty microlitres of a precision pre-stained 10 - 250 kDa molecular weight 
marker (Bio-Rad, USA) was loaded in the first lane to assist with the orientation and 
size determination of separated proteins. 
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Proteins were fractioned by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) on a Mini-PROTEAN® Tetra cell vertical 
electrophoresis system (Bio-Rad, USA) at a constant voltage of 150 V (AA Hoefer 
Power Pac PS300-B, USA) until the gel front reached the bottom of the gel. 
 
2.10. Western Blotting and Immunoblot 
To establish whether the targets of interest are expressed by the cell models used, 
unirradiated and irradiated cells were assayed for protein levels, by Western blotting 
with antibodies specific for HER-2, PI3K and mTOR.  
The resolved proteins were electro-transferred onto a polyvinylidene difluoride 
membrane (PVDF Immun-Blot™) (Bio-Rad, USA) for 2½ hours on ice at a current of 
200 mA, using a vertical wet transfer system (Mini- PROTEAN® Tetra cell) (Bio-Rad, 
USA). 
The proteins were transferred from the gel to the membrane in transfer buffer 
containing glycine (192 mM), Tris (25 mM) and methanol (20%).  
 
2.11. Ponceau S Staining of PVDF Membranes 
PVDF membranes were stained with Ponceau S (Sigma-Aldrich, Germany) to 
expose the protein bands and allow for an assessment of sample loading. Following 
protein transfer by electroblotting, membranes were soaked in Ponceau S for 60 
seconds and rinsed in distilled water, before blocking with Tris buffered saline with 
Tween 20 (TBST) containing 5% non-fat milk. 
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2.12. Immuno-detection 
The membranes were blocked in Tris buffered saline with Tween 20 (TBST) 
containing 5% non-fat milk (Elite fat free milk powder, Clover SA (Pty) Ltd) for 25 
minutes at room temperature, followed by two washes in Tris buffered saline 
(TBS)/Tween 20 solution for 5 minutes each, before the primary antibodies were 
added and membranes left rotating overnight at 4°C. The final concentration of each 
specific primary antibody on the membrane was 1:1000, as per supplier’s 
instructions. Incubation in primary antibodies against PI3K, Anti-PI3 Kinase p110 
beta antibody (ab5593) (Abcam, UK), HER-2,  Neu 3B5: sc-33684 (Santa Cruz 
Biotechnology Inc., USA), mTOR, mTOR (7C10) Rabbit mAb (Cell Signaling Inc., 
USA) was followed by  3 five-minute washes in TBS/Tween 20 solution, before the 
addition of a secondary antibody goat anti-rabbit IgG horseradish peroxidase 
antibody (Santa Cruz Biotechnology, USA) and incubated for 2 hours at room 
temperature. The concentration of each specific secondary antibody was also 
1:1000, as per supplier’s instructions. The membranes were then washed several 
times in TBS/Tween 20 solution, before protein detection. 
 
2.13. Western Blotting Detection System 
Following Western blot transfer the immobilised proteins were detected using the 
tetramethylbenzidine membrane peroxidase substrate system (KPL Inc., USA). This 
is a sensitive colorimetric detection method for the presence of peroxidase 
conjugates. Immersion of the membrane in TMB for 15 minutes at room temperature 
permitted easy visualisation of the blue bands.   
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2.14. Data Analysis 
Data are presented as the mean ± standard error of the mean (SEM) of three 
independent experiments as indicated by error bars. Statistical analysis and data 
fitting were performed by means of GraphPad Prism (GraphPad Software, San 
Diego, USA). A two-sided Student’s t-test was used to compare the means between 
sample groups, p-values < 0.05 were declared significant.                       
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CHAPTER 3 
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3.  Results 
 
3.1. Radiosensitivity 
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Figure 2: Clonogenic survival curve for the breast carcinoma cell lines MDA-MB-231 
and MCF-7 after 60Co γ-irradiation. Symbols represent the mean (±SEM) surviving 
fraction from 3 independent experiments. The survival curve was obtained by fitting 
experimental data to the linear-quadratic model. 
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The relative radiosensitivity of MDA-MB-231 (MDA) and MCF-7 was evaluated using 
the clonogenic cell survival assay. Cell survival data for the human breast carcinoma 
cell lines were fitted to the linear-quadratic model and are presented in Figure 2.  
From the dose-response curves presented in Figure 2, it is apparent that the breast 
carcinoma cell line MCF-7 is more radiosensitive than the MDA-MB-231 cell line. 
This is consistent with the relatively steeper survival curve for MCF-7 than for MDA-
MB-231. The α- and β-coefficients for the MCF-7 and MDA-MB-231 cell lines were 
0.14  0.10 Gy-1 and 0.06  0.01 Gy-2 and 0.21  0.04 Gy-1 and 0.01  0.01 Gy-2, 
respectively.  For comparison, intrinsic cellular radiosensitivity was expressed in 
terms of the surviving fraction at 2 Gy (SF2). The MDA-MB-231 cell line was found to 
be marginally more radioresistant than MCF-7, on the basis of SF2. The SF2-values 
emerged as 0.64 ± 0.09 and 0.58 ± 0.02 for the MDA-MB-231 and MCF-7 cell lines, 
respectively (P = 0.0528). 
 
3.2. Cytotoxicity of Inhibitors  
 
To assess the cytotoxicity of the PI3K, mTOR and HER-2 inhibitors, plating 
efficiencies (PE) for cell cultures were determined in the presence of the inhibitors, 
either singly or in combination, and compared with those obtained for cells cultured 
without inhibitors. The PE-values for the MDA cell line were found to be 0.2867  
0.1105 and 0.2500  0.0700 in the absence and presence of BEZ235, respectively, 
and was the same as that observed (P = 0.7931). Treatment of these cells with 17.5 
nM BEZ235 does not result in cell kill, based on colony formation. The PE-value for 
TAK-165 emerged as 0.1967  0.0694 and was not significantly different from the PE 
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without inhibitor (P = 0.5282), corresponding to no cell kill. The plating efficiency in 
MDA cultures treated with a cocktail of the two inhibitors was 0.2967  0.1102, and 
was the same as that observed in untreated cultures (P = 0.9520).  
For the MCF-7 cell line, the plating efficiencies were 0.1967  0.0120 and 0.0559  
0.0228 in the absence and presence of BEZ235, respectively, and were significantly 
different (P = 0.0055). BEZ235 induced a 72% cell kill in this cell line. The plating 
efficiency in TAK-165 treated MCF-7 cultures was 0.0820  0.0006 and differed 
significantly from that obtained for untreated cultures (P = 0.0007). TAK-165 
treatment results were about 58% cell kill in MCF-7 cultures. The PE-value for MCF-
7 cells following treatment with a cocktail of the two inhibitors was found to be 0.0530 
 0.0231 and was also significantly different from the PE for untreated cultures (P = 
0.0052), giving a 73% cell kill indicating that the addition of TAK-165 and BEZ235 
does not seem to have an effect on cell adherence.       
 
3.3. Modulation of Radiosensitivity of MDA and MCF-7 at 2 Gy 
 
To assess whether blocking the activities of HER-2, PI3K and mTOR with specific 
inhibitors results in changes in cellular radiosensitivity, cell cultures were treated with 
TAK-165 (against HER-2) and BEZ235 (against PI3K and mTOR), and subsequently 
irradiated with 2 Gy. The cell survival data for MDA-MB-231 and MCF-7 are shown in 
Figures 3 and 4.   
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Figure 3: Clonogenic cell survival at 2 Gy of 60Co γ-irradiation for a 
human breast carcinoma cell line (MDA-MB-231) following single or 
combined (cocktail) treatment with TAK-165 (HER-2 inhibitor) and 
BEZ235 (PI3K and mTOR inhibitor).  
 
Treatment with TAK-165 alone sensitised MDA cells, resulting in a reduction in SF2 
from 0.55 ± 0.07 to 0.48 ± 0.03. The radiosensitisation was not statistically significant 
(P = 0.4395). A higher radiosensitisation was observed when MDA cells were pre-
treated with BEZ235, with SF2 decreasing from 0.55 ± 0.07 to 0.41 ± 0.08 (P = 
0.2377). The SF2 values in the presence of the two agents were not significantly 
different (P = 0.4006). When the cells were treated with a cocktail of TAK-165 and 
BEZ235, the surviving fraction at 2 Gy emerged as 0.27 ± 0.04 and was significantly 
lower than that obtained for TAK-165 treatment (P = 0.0181). A higher, but not 
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significantly different, radiosensitisation was obtained for cocktail treatment, 
compared with that for BEZ235 (P = 0.2006).  
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Figure 4: Clonogenic cell survival at 2 Gy of 60Co γ-irradiation for a 
human breast carcinoma cell line (MCF-7) following single or combined 
(cocktail) treatment with TAK-165 (HER-2 inhibitor) and BEZ235 (PI3K 
and mTOR inhibitor). 
 
The corresponding data for the MCF-7 cell line is presented in Figure 4. MCF-7 cells 
pre-treated with TAK-165 alone resulted in a reduction in surviving fraction at 2 Gy 
from 0.32 ± 0.05 to 0.27 ± 0.06 (P = 0.5452), indicating no significant cellular 
sensitisation. An increase in radiosensitisation was observed when cells were pre-
treated with BEZ235 and exposed to 2 Gy of ionising radiation, resulting in a 
decrease in SF2 from 0.32 ± 0.05 to 0.23 ± 0.04 (P = 0.2081). Cellular treatment with 
a BEZ235/TAK-165 cocktail appeared to have an effect on the radiosensitivity of the 
MCF-7 cells, resulting on a surviving fraction at 2 Gy of 0.32 ± 0.05 to 0.21 ± 0.04 (P 
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= 0.1798). Although the trend indicates an increase in radiosensitivity when cells 
were treated with a cocktail of BEZ235 and TAK-165, statistically there was no 
difference (P>0.05).  
 
3.4. Modulation of Radiosensitivity of MDA and MCF-7 at 6 Gy 
 
To investigate whether the apparent radiosensitisation seen in both breast carcinoma 
cell lines exist at higher fractional doses, as may be encountered in hypofractionated 
treatments, cell culture were also treated with the inhibitors of HER-2, PI3K and 
mTOR, irradiated to 6 Gy, and were assessed for clonogenic survival. The cell 
survival data are presented in Figures 5 and 6 for MDA-MB-231 and MCF-7, 
respectively. 
The data in Figure 5 show no difference in cell survival when MDA-MB-231 cells 
were pre-treated with TAK-165 and exposed to 6 Gy. The surviving fractions at 6 Gy 
(SF6) were 0.17 ± 0.02 to 0.16 ± 0.03 for control and inhibitor treated cell cultures, 
respectively (P = 0.8554). When cells were pre-treated with BEZ235 alone, SF6 
decreased from 0.17 ± 0.02 to 0.11 ± 0.02 (P = 0.1242). BEZ235 appeared to be a 
better radiosensitiser than TAK-165 of MDA cells at 6 Gy. Cocktail pre-treatment 
showed a higher, but not significantly different, sensitising effect than TAK-165 and 
BEZ235 individually, giving an SF6 of 0.09 ± 0.02 (P  0.0835).  
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Figure 5: Clonogenic cell survival at 6 Gy of 60Co γ-irradiation for a 
human breast carcinoma cell line (MDA-MB-231) following single or 
combined (cocktail) treatment with TAK-165 (HER-2 inhibitor) and 
BEZ235 (PI3K and mTOR inhibitor). 
 
 
The surviving fraction at 6 Gy decreased marginally from 0.12 ± 0.04 to 0.08 ± 0.01 
(P = 0.4103) when MCF-7 cells were treated with TAK-165 alone (Figure 6). BEZ235 
treatment resulted in a similar level of radiosensitisation as obtained for TAK-165, 
with SF6 of 0.07 ± 0.02 (P = 0.3791). Treatment of these cells with a cocktail of TAK-
165 and BEZ235 did not give rise to a higher level of radiosensitisation than when 
BEZ235 and TAK-165 were used individually. The SF6 for cocktail treatment was 
0.06 ± 0.03 (P  0.5081).       
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Figure 6: Clonogenic cell survival at 6 Gy of 60Co γ-irradiation for a 
human breast carcinoma cell line (MCF-7) following single or combined 
(cocktail) treatment with TAK-165 (HER-2 inhibitor) and BEZ235 (PI3K 
and mTOR inhibitor). 
 
 
To further evaluate the effect of inhibitors on radiation-induced cell kill, radiation 
enhancement factors (REF) were calculated for each cell line and treatment scenario 
from the data presented in Figures 3 - 6. The radiosensitivity data for the MDA-MB-
231 and MCF-7 cell lines are summarised in Table 3 and Table 4, respectively.  
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Table 3:  Radiation enhancement data at 2 and 6 Gy for MDA-MB-231 cells 
treated with TAK-165 and BEZ235. 
 
Treatment SF REF* 
2 Gy (no inhibitor)  0.55 ± 0.07  
2 Gy + TAK-165  0.48 ± 0.03 1.15 ± 0.16 
2 Gy + BEZ235  0.41 ± 0.08 1.34 ± 0.31 
2 Gy + Cocktail  0.27 ± 0.04 2.04 ± 0.40 
   
6 Gy (no inhibitor)  0.17 ± 0.02  
6 Gy + TAK-165  0.16 ± 0.03 1.06 ± 0.23 
6 Gy + BEZ235  0.11 ± 0.02 1.55 ± 0.34 
6 Gy + Cocktail  0.09 ± 0.02 1.89 ± 0.48 
 
*Error calculated using an appropriate error propagation formula 
  
 
In Table 3, it is observed that, on average, treatment of MDA cells with BEZ235 
results in a higher level of radiation enhancement than TAK-165 at 2 Gy. Cocktail 
treatment showed a 2-fold radiation enhancement (Equation (2)). At 6 Gy, TAK-165 
did not appear to have an effect on the radiosensitivity of MDA cells (Table 3). On the 
other hand, treatment with BEZ235 led to a higher radiosensitisation than that 
obtained for 2-Gy irradiation. Cocktail therapy preceding 6 Gy of radiation yielded a 
similar level of enhancement as in the case of 2 Gy (Table 3).  
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Table 4:  Radiation enhancement data at 2 and 6 Gy for MCF-7 cells treated 
with TAK-165 and BEZ235. 
 
Treatment SF REF* 
2 Gy (no inhibitor)  0.32 ± 0.05  
2 Gy + TAK-165  0.27 ± 0.06 1.19 ± 0.32 
2 Gy + BEZ235  0.23 ± 0.04 1.39 ± 0.33 
2 Gy + Cocktail  0.21 ± 0.04 1.52 ± 0.37 
   
6 Gy (no inhibitor)  0.12 ± 0.04  
6 Gy + TAK-165  0.08 ± 0.01 1.50 ± 0.53 
6 Gy + BEZ235  0.07 ± 0.02 1.71 ± 0.75 
6 Gy + Cocktail  0.06 ± 0.03 2.00 ± 1.20. 
 
*Error calculated using an appropriate error propagation formula. 
 
 
 
From the radiosensitivity enhancement data, BEZ235 emerged as a better 
radiosensitiser of MCF-7 cells than TAK-165 (Table 4). A higher sensitisation 
resulted from cocktail treatment. A similar trend in radiosensitisation was seen at 6 
Gy, although the extent of radiation enhancement was in all treatment scenarios 
higher than those at 2 Gy. A 2-fold radiosensitisation was also obtained when MCF-7 
cells were pre-treated with a BEZ235/TAK-165 cocktail.  
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3.5. Western Blot Analysis 
 
3.5.1 Ponceau Stain 
Figure 7 shows an image of a PVDF membrane that has been Ponceau stained after 
it has been through protein transfer for MDA-MB-231 cells.  The Ponceau stain is a 
general stain and is used to determine if the transfer of proteins has taken place. 
Bands representing the standard protein ladder and samples are illustrated with 
arrows to indicate the relative positions of the target proteins: mTOR, HER-2 and 
PI3K. Ponceau staining of the PVDF membrane for the MCF-7 cell line produced a 
similar image.    
 
 
 
 
 
 
 
 
 
 
Figure 7: An image of a PVDF membrane that has been Ponceau stained 
after the transfer of proteins MDA-MB-231 cells. 
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75 kDa 
37 kDa 
mTOR 
HER-2 
PI3K 
Ladder              Protein Samples              
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3.5.2. Immuno-Blots 
 
Figure 8 is an image of a PVDF membrane developed from unirradiated and 
irradiated MDA-MB-231 cells. Immuno-detection for total protein was used to identify 
HER-2, PI3K and mTOR. All proteins were expressed. Neither radiation dose nor 
incubation time of the order of 6 hours had an impact on the expression levels of the 
target proteins. Immuno-blotting of the MCF-7 membranes were unsuccessful.  
 
 
 
 
 
 
 
 
 
Figure 8: An immuno-blot of total HER-2, PI3K and mTOR expression. 
Protein samples were loaded in duplicate: Lanes 1 (unirradiated control); 
Lanes 2 (2 Gy with no incubation); and Lanes 3 (2 Gy with a 6-hour 
incubation).  
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4. Discussion 
 
4.1. Cellular Resistance to Radiotherapy 
 
Radiotherapy has become part of standard care in both curative and palliative breast 
cancer treatment (Katz et al., 2009; Pearce et al., 2001). However, inherent or 
acquired radioresistance is thought to be the reason why many tumours do not 
respond favourably to radiotherapy (Jung et al., 2011; Li et al., 2012; Liang et al., 
2003). It has been shown that the treatment of breast cancer cells with 2 - 6 Gy of 
radiation results in the elimination of radiosensitive sub-populations of cells, leaving 
the radioresistant cells to repopulate (Pearce et al., 2001). It is assumed that the 
surviving and repopulating carcinoma cells are capable of providing molecular 
protection against the cytotoxic effects of radiation therapy.  
 
This research aimed to investigate radio-enhancement for a better therapeutic 
outcome. Knowledge of the differential radiosensitivity of breast tumours could 
provide a basis for adjuvant radiotherapy approaches, and help optimise breast 
cancer management. To address this need, two breast carcinoma cell lines (MDA-
MB-231 and MCF-7) with different intrinsic radiosensitivities were used in this study. 
 
Figure 2 shows the cell survival curves for the MDA-MB-231 and MCF-7 cell lines. 
Although the two cell lines appeared to exhibit similar radiation response at low 
doses (SF2 of 0.64 and 0.58 for MDA-MB-231 and MCF-7, respectively), their 
radiosensitivities differ significantly at higher doses. While the survival curve of the 
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radiosensitive MCF-7 cell line has a prominent shoulder (smaller α/β ratio of 2.33 
Gy), that for its more radioresistant MDA-MB-231 counterpart shows virtually no 
shoulder (large α/β ratio of ~21 Gy). The α/β ratio is the dose at which the linear and 
quadratic components of cell killing are equal. This relative radiosensitivity between 
these cell lines is consistent that reported elsewhere (Albert et al., 2008). The 
phosphatase and tensin homolog (PTEN) which impedes PI3K/mTOR pathway 
activity to sensitise cells to cytotoxic insult is wildly expressed in both cell lines 
(Carlson et al., 2010; Lue et al., 2007). Therefore, the observed differences in 
radiosensitivity, as illustrated in Figure 2, cannot be attributed to disparities in PTEN 
activity. While the more radioresistant MDA-MB-231 cell line is known to express 
wild-type PI3K, the radiosensitive MCF-7 cells are PI3K mutant (Vasudevan et al., 
2009; Carlson et al., 2010). A reduction in PI3K/mTOR signalling in MCF-7 cells due 
to the PI3K mutation can compromise their ability to recover from radiation-induced 
damage. 
 
 
4.2. Simultaneous Inhibition of HER-2 and PI3K Pathways Enhance 
Radiosensitivity of Breast Cancer Cells 
 
There is evidence to show that inhibition of proteins involved in the PI3K/Akt/mTOR 
pathway can enhance cancer cell radiosensitisation (Awada et al., 2012; Rexer et 
al., 2014). Therefore, targeting of survival proteins, like PI3K, Akt, and mTOR, could 
improve HER-2 targeted treatment response in subtypes of breast cancer that show 
low or no expression of HER-2. Targeted therapy has improved overall patient 
survival, but its efficacy has been limited by inherent or acquired cellular resistance 
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(Higgins and Baselga, 2011; Hurvitz et al., 2013). Successes in targeted therapy 
using single agents are marginal, and it has been argued that treating with multiple 
agents could lead to better patient responses (Normanno et al., 2009). 
 
This study explored whether the dual inhibitor of PI3K and mTOR, BEZ235, and 
TAK-165 which is an HER-2 inhibitor, could sensitise human breast cancer cells to 
ionising radiation. Furthermore, the study assessed whether a cocktail of the two 
inhibitors would yield a greater radiosensitisation in cells, in comparison to a single 
inhibitor. The effects of the inhibitors combined with radiation were assessed at a 
cellular level, and clonogenic survival was measured. At the molecular level 
expression of HER-2, PI3K and mTOR was evaluated using Western blot analysis. 
Targeting the HER-2 pathway by inhibiting PI3K has been shown to inactivate the 
PI3K/Akt/mTOR pathway and significantly radiosensitise cancer cells (No et al., 
2009; Riesterer et al., 2004). This is in agreement with the results presented here. 
Pre-treatment of MDA-MB-231 cells with the dual inhibitor of PI3K and mTOR, 
BEZ235, reduced the surviving fractions at 2 and 6 Gy, giving average radiation 
enhancement factors of 1.34 and 1.55, respectively (Figures 3 and 5; Table 1). The 
sensitisation at both radiation doses was similar. This suggests that 
radiosensitisation of MDA-MB-231 cells via inhibition of PI3K and mTOR is likely 
independent of radiation dose, and that BEZ235 could potentially be used as a 
radiosensitiser in conventional, as well as, hypofractionated radiotherapy. Similar 
levels of radiation enhancement were seen in the relatively more sensitive MCF-7 
cell line (Figures 4 and 6; Table 2). The marked disparity between radiosensitisation 
observed here and the ~4-fold radiosensitisation reported elsewhere (Kuger et al., 
2014), might be due to differences in experimental design. The BEZ235 
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concentration of 100 nM used by Kuger and colleagues was ~6 times that used in 
the present study (Kuger et al 2014), and correspond to BEZ235 doses at which very 
few cells would be expected to survive if the residence time of the drug was over the 
entire colony forming period. Drug cytotoxicity strongly depends on residence time 
(Akudugu and Slabbert, 2008). Trypsinisation and plating of cells a day after drug 
and radiation treatment can also affect extent to which the drug modulates 
radiosensitivity.  In contrast to BEZ235 treatment, exposure of MDA-MB-231 cells to 
the HER-2 inhibitor TAK-165 had virtually no effect on the radiosensitivity at 2 and 6 
Gy (Figures 3 and 5; Table 3). The response of MCF-7 cells at 2 Gy to treatment 
with the HER-2 TAK-165 was comparable to that of MDA-MB-231 cells (Figures 4 
and 6; Table 4). However, TAK-165 treatment yielded an enhancement factor of 1.50 
at 6 Gy, indicating that certain breast cancer subtypes may benefit from combining 
HER-2 targeted therapy with high radiation doses. As expected, the lack or minimal 
radiosensitisation seen in both cell lines may be attributed to the fact that they do not 
overexpress HER-2 (Konecny et al., 2006; Subik et al., 2010). Therefore, the role of 
HER-2 perturbation in radiosensitivity modulation would be minimal. This is 
consistent with data reported elsewhere indicating that trastuzumab (a potent HER-2 
inhibitor) had little or no effect on radiation-induced apoptosis in breast cancer cell 
lines that show low to no expression of HER-2 (Liang et al 2003).  
 
It is important to focus not only on the upstream target, HER-2, but also on the 
downstream targets, PI3K and mTOR, since inhibition of only one target upstream or 
downstream may not fully counteract the resistance of cells to irradiation. Co-
targeting HER-2, PI3K and mTOR may, theoretically, maximise the radiosensitivity of 
cancer cells. The rationale or the desired expectation for this combination therapy 
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approach is to target sub-populations of tumour cells that may be resistant to one or 
other cytotoxic agent, and, furthermore, to simultaneously target all cells on a cell-by-
cell basis (Akudugu and Howell., 2012a, b; Akudugu et al., 2011; Kvinnsland et al., 
2001). Pre-treatment with a cocktail of TAK-165 and BEZ235 seems to be superior 
at radiosensitising both breast cancer cell lines than when cells were exposed to 
each agent individually (Tables 3 and 4). A 2-fold and dose-independent 
radiosensitisation emerged, suggesting that concomitant inhibition of HER-2, PI3K 
and mTOR in breast cancer radiotherapy modalities that employ low to high 
fractional doses might be beneficial. However, it would be desirable to demonstrate 
that the cocktail is non-toxic in normal tissue.  
       
The apparent radiosensitisation observed here notwithstanding, it is worth noting that 
TAK-165 and BEZ235 were cytotoxic in both cell lines. This suggests that 
interference with the HER-2 and PI3K/Akt/mTOR pathways without concomitant use 
of radiotherapy might have a therapeutic benefit. Further evaluation, on the bases of 
inhibitor concentration and inhibitor residence time, would be needed to ascertain 
whether the apparent benefit could be maximised with addition of radiation 
threatment. In additional, studies on the effect of BEZ235 and TAK-165 on normal 
breast cell lines are desirable for optimisation of these findings.  
 
4.3. Target Expression in Breast Cells 
To demonstrate capacity to detect expression of the pathway targets, Western blot 
analyses were performed on the cell lines. An immuno-blot for total protein shows 
presence of mTOR, HER-2, and PI3K in MDA-MB-231 (Figure 8). Detection of the 
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phosphorylated protein would be required to confirm activity status of each target. 
Although MCF-7 cells are EGFR, HER-2, ER and PR positive (Horwitz et al., 1975; 
Rusnak et al., 2001), its expression of HER-2 is low and comparable to that in the 
MDA-MB-231 cells (Konecny et al., 2006). While expression of EGFR in MCF-7 cells 
is also low, MDA-MB-231 cells which are known to be ER and PR negative (Read et 
al., 1988), express high levels of EGFR (Konecny et al., 2006; Subik et al., 2010). 
This indicates that the MDA-MB-231 cell line can potentially be used as a model for 
triple-negative breast cancer if its residual HER-2 is successfully inhibited. The 
apparent radiosensitisation induced by BEZ235 and TAK-165 may have significant 
implications for breast cancer expressing little to no HER-2. The MDA-MB-231 cell 
line is known to express wild-type PI3K, but PI3K is mutated in MCF-7 cells 
(Vasudevan et al., 2009; Carlson et al., 2010). Processing of radiation-induced 
damage in MCF-7 cells can, therefore, involve components other than PI3K. In 
addition to HER-2, TAK-165 is a potent inhibitor of the cell division cycle protein 2 
homolog (Cdc2), which plays a crucial role in cell cycle progression. Perturbation of 
Cdc2 activity with TAK-165 can lead to cell cycle arrest and subsequent cellular 
demise during cell division. Cdc2 activity in MDA-MB-231 is intrinsically higher than 
that in MCF-7 (Pozo-Guisado et al., 2002; Kuo et al., 2006), indicating a stronger 
dependence of former cell line on Cdc2 activity for cell cycle progression. Therefore, 
inhibiting residual HER-2 and Cdc2 activity with TAK-165 can be expected to make 
MDA-MB-231 cells more susceptible to cytotoxic insult than their MCF-7 
counterparts.  However, this cannot be support by the current findings as there is no 
clear differential between modulation of radiosensitivity by BEZ235 and TAK-165 in 
the two cell lines. 
   
Stellenbosch University  https://scholar.sun.ac.za
57 
 
 
4.4. Possible Future Avenues for Research 
 
1. It would be of interest to validate the apparent radiosensitisation of the cancer 
cell line, using lower concentrations of the target inhibitors. This may provide 
useful information on the optimum inhibitor doses that can be used without 
inducing undue normal tissue toxicity;  
 
2. Further molecular evaluation of the activity status of the targets by detection 
and measurement of the corresponding phosphorylated target proteins would 
shed more light on the signalling mechanisms underlying the radiation 
responses; 
 
 
3. Studies seeking to determine whether blocking PI3K and mTOR with BEZ235, 
or HER-2 with TAK-165 leads to radiosensitisation or radiation protection in 
normal cells would have significant benefit not only in radiotherapy, but also in 
radiation protection.  
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CHAPTER 5 
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5. Conclusion 
 
In the current study, it has been shown that human breast cancer cell lines MDA-MB-
231 and MCF-7 have similar radiosensitivity at relatively low doses, with the former 
being significantly more radioresistant than the latter at much higher doses. 
Treatment of the cell lines with inhibitors of HER-2, PI3K, and mTOR, singly or in 
combination, at low and relatively high radiation doses resulted in a measurable but 
not significant radiosensitisation. Inhibition of PI3K and mTOR appeared to show 
better potentiation of radiosensitivity, PI3K and mTOR might be potential therapeutic 
targets in breast cancers devoid of HER-2 expression. Further studies interrogating 
the roles of PI3K and mTOR in cellular responses to drug and radiation treatment 
can make a significant contribution towards the formulation of patient-specific 
therapeutic cocktails that will revolutionise the treatment of breast cancer. 
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